13 completed, 4 recruiting, 1 unknown, 1 withdrawn. 19 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 19 | Completed 13, Recruiting 4, Unknown 1, Withdrawn 1 |
Follow oxybutynin: new trials by email Literature Review of oxybutynin trials Research Report on oxybutynin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction Oxybutynin Hydrochloride, Placebo - Spina Bifida | Phase 3 | Recruiting | Central Hospital, Nancy, France | 60 | 2026-01-15 | 2026-04-14 |
| Efficacy and Safety of Tamsulosin for Children with Posterior Urethral Valve. Tamsulosin, Oxybutynin, Trimethoprim/sulfamethoxazole (TMP/SMZ) - Posterior Urethral Valve | Phase 3 | Recruiting | Mansoura University | 50 | 2024-11-01 | 2024-12-20 |
| REDucing Hot FLASHes in Women Using Endocrine Therapy. Oxybutynin, Venlafaxine - Breast Cancer, Hot Flash Due to Medication | Phase 3 | Recruiting | Reinier de Graaf Groep | 260 | 2024-10-03 | 2025-02-04 |
| Oxybutynin for Post-surgical Bladder Pain and Urgency Oxybutynin Transdermal Patch, Oral Oxybutynin - Overactive Bladder Syndrome, Neuropathic Bladder | Phase 3 | Recruiting | University of California, Davis | 100 | 2021-09-01 | 2026-01-29 |
| Oxybutynin Chloride in Managing Hot Flashes Oxybutynin Chloride, Placebo, Quality-of-Life Assessment - Breast Carcinoma, Ductal Breast Carcinoma In Situ | Phase 3 | Completed | Academic and Community Cancer Research United | 150 | 2016-12-09 | 2020-01-18 |
| Evaluate the Efficacy of Oxybutynin Chloride in Patients With Primary Hyperhidrosis Oxybutynin, Placebo - Hyperhidrosis | Phase 3 | Withdrawn | Cristália Produtos Químicos Farmacêuticos Ltda. | 2015-12-01 | 2016-07-26 | |
| Muscarinic Receptor Antagonists as a Therapy for Diabetic Neuropathy 3% oxybutynin, Placebo - Diabetic; Neuropathic, Polyneuropathy (Manifestation) | Phase 3 | Completed | Eastern Virginia Medical School | 51 | 2014-05-01 | 2019-02-22 |
| OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER onaBoNT-A, Oxybutynin ER - Overactive Bladder | Phase 3 | Unknown | Christopher Patrick Smith | 36 | 2013-08-01 | 2016-08-30 |
| Minirin Versus Oxybutynin for Nocturnal Enuresis in Children Minirin, Oxybutynin - Nocturnal Enuresis | Phase 3 | Completed | Hormozgan University of Medical Sciences | 66 | 2013-07-01 | 2015-09-02 |
| Treatment of Hyperhidrosis With Oxybutynin Oxybutynin, Placebo - Hyperhidrosis | Phase 3 | Completed | University Hospital, Brest | 62 | 2013-06-01 | 2025-12-03 |
| A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By A Neurological Condition Fesoterodine PR 4 mg, Fesoterodine PR 8 mg, Oxybutynin - Urinary Bladder, Neurogenic | Phase 3 | Completed | Pfizer | 181 | 2012-07-02 | 2021-02-02 |
| Botox Versus Oxybutynin as First Line Treatment for the Poorly Compliant Pediatric Neurogenic Bladder Oxybutynin, Botulinum Toxin A injection - Neurogenic Bladder | Phase 3 | Completed | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 20 | 2011-05-01 | 2012-10-30 |
| Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream. Oxybutynin (Oxytrol, BAY839380) - Overactive Bladder | Phase 3 | Completed | Bayer | 855 | 2010-05-25 | 2020-10-20 |
| Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence Oxybutynin, Placebo - Urge Urinary Incontinence, Urinary Frequency | Phase 3 | Completed | Antares Pharma Inc. | 626 | 2009-03-01 | 2014-07-02 |
| A Comparison of a New Drug to Treat Overactive Bladder vs. Placebo Oxybutynin topical gel, Placebo topical gel - Overactive Bladder | Phase 3 | Completed | Watson Pharmaceuticals | 789 | 2006-06-01 | 2010-05-10 |
| Behavioral Treatment of Overactive Bladder in Men Behavioral training, Oxybutynin chloride, extended-release - Overactive Bladder | Phase 3 | Completed | US Department of Veterans Affairs | 143 | 2005-01-01 | 2014-05-20 |
| A Study Comparing the Efficacy and Safety of OROS® Oxybutynin to That of Ditropan® (Immediate-release Oxybutynin) for the Treatment of Patients With Urge or Mixed Urinary Incontinence. OROS® oxybutynin or Ditropan® - Urge Incontinence | Phase 3 | Completed | Alza Corporation, DE, USA | 100 | 1996-07-01 | 2011-05-19 |
| Efficacy and Safety of OROS Oybutynin and TTS Oxybutynin in Middle-Aged and Elderly Women With Urinary Incontinence Oxybutynin - Urinary Incontinence | Phase 3 | Completed | Alza Corporation, DE, USA | 176 | 1995-12-01 | 2011-05-19 |
| Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder oxybutynin chloride - Urinary Incontinence | Phase 3 | Completed | Alza Corporation, DE, USA | 790 | 2025-02-03 |
Urinary Bladder, Overactive (4) · Urinary Incontinence (4) · Urinary Bladder, Neurogenic (3) · Urinary Incontinence, Urge (3) · Breast Neoplasms (2) · Hyperhidrosis (2) · Breast Carcinoma In Situ (1) · Carcinoma, Intraductal, Noninfiltrating (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Hot Flashes (1) · Lower Urinary Tract Symptoms (1) · Nocturnal Enuresis (1) · Polyneuropathies (1) · Spinal Cord Injuries (1) · Spinal Dysraphism (1)
Alza Corporation, DE, USA (3) · Academic and Community Cancer Research United (1) · Antares Pharma Inc. (1) · Bayer (1) · Central Hospital, Nancy, France (1) · Christopher Patrick Smith (1) · Cristália Produtos Químicos Farmacêuticos Ltda. (1) · Eastern Virginia Medical School (1) · Hormozgan University of Medical Sciences (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Mansoura University (1) · Pfizer (1) · Reinier de Graaf Groep (1) · US Department of Veterans Affairs (1) · University Hospital, Brest (1)
United States (9) · France (3) · Canada (2) · Belgium (1) · Brazil (1) · Egypt (1) · Estonia (1) · Finland (1) · Germany (1) · Greece (1) · India (1) · Iran (1) · Italy (1) · Japan (1) · Lithuania (1)
Aaron I Vinik, MD, PhD (1) · Ahmed Elkashef (1) · Ashraf Tarek Hafez (1) · Charles Loprinzi (1) · Christopher P. Smith, MD (1) · Eric A Kurzrock, MD (1) · Hamidreza Mahboobi, M.D (1) · Kathryn L. Burgio, PhD MA BA (1) · Kim Caramelli, MS (1) · Lemonitsa Mammatas, PhD (1) · Mohamed Hussiny (1)
PMID 37160401, PMID 12934777, PMID 19233423, PMID 19625056, PMID 19683731, PMID 22092152, PMID 23448285, PMID 24477421, PMID 26114588, PMID 27123229, PMID 30266334, PMID 36504158, PMID 36892754, PMID 37811598, PMID 38526612, PMID 41178302
P30CA015083 (1)